AG2R LA Mondiale Gestion D Actifs Makes New $1.73 Million Investment in Kenvue Inc. $KVUE

Key Points

• AG2R LA Mondiale Gestion D Actifs has acquired 72,256 shares of Kenvue Inc., valued at approximately $1.725 million, as reported in its recent Form 13F filing.
• Analysts have adjusted their price targets for Kenvue Inc., with JPMorgan lowering it from $27.00 to $26.00, while the consensus rating remains a "Hold" with an average price target of $24.21.
• Kenvue recently announced an increase in its quarterly dividend to $0.2075 per share, resulting in an annualized dividend yield of 4.4%.

AG2R LA Mondiale Gestion D Actifs bought a new stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 72,256 shares of the company's stock, valued at approximately $1,725,000.

Several other institutional investors and hedge funds also recently made changes to their positions in KVUE. Starboard Value LP bought a new position in shares of Kenvue during the fourth quarter valued at about $467,864,000. Vanguard Group Inc. grew its position in Kenvue by 4.9% during the 1st quarter. Vanguard Group Inc. now owns 229,144,387 shares of the company's stock worth $5,494,882,000 after acquiring an additional 10,600,682 shares during the last quarter. Third Point LLC bought a new position in Kenvue during the 1st quarter worth approximately $213,422,000. Maverick Capital Ltd. bought a new position in Kenvue during the 1st quarter worth approximately $203,036,000. Finally, Nuveen LLC bought a new position in Kenvue during the 1st quarter worth approximately $187,123,000. Institutional investors own 97.64% of the company's stock.

Kenvue Stock Down 1.0%

Kenvue stock traded down $0.18 during trading hours on Tuesday, hitting $18.07. 19,679,218 shares of the stock traded hands, compared to its average volume of 18,447,689. The company has a current ratio of 0.98, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a one year low of $17.15 and a one year high of $25.17. The company has a market cap of $34.68 billion, a PE ratio of 24.42, a PEG ratio of 2.73 and a beta of 0.83. The firm's 50-day moving average price is $21.04 and its two-hundred day moving average price is $22.16.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.28 by $0.01. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The company had revenue of $3.84 billion for the quarter, compared to analyst estimates of $3.94 billion. During the same period in the previous year, the company posted $0.32 earnings per share. The firm's revenue was down 4.0% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, research analysts forecast that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th were paid a dividend of $0.2075 per share. The ex-dividend date of this dividend was Wednesday, August 13th. This is an increase from Kenvue's previous quarterly dividend of $0.21. This represents a $0.83 annualized dividend and a yield of 4.6%. Kenvue's payout ratio is presently 112.16%.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on KVUE shares. Royal Bank Of Canada cut their target price on shares of Kenvue from $24.00 to $22.00 and set a "sector perform" rating on the stock in a report on Friday, August 8th. Barclays cut their price target on shares of Kenvue from $23.00 to $22.00 and set an "equal weight" rating on the stock in a report on Tuesday, July 15th. Evercore ISI cut their target price on Kenvue from $25.00 to $23.00 and set an "in-line" rating on the stock in a research note on Monday, September 8th. Zacks Research raised Kenvue to a "strong sell" rating in a research note on Monday, August 11th. Finally, Citigroup cut their price objective on Kenvue from $22.00 to $20.00 and set a "neutral" rating on the stock in a research report on Tuesday. Five equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $24.04.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.